DuPont de Nemours, Inc. · NYSE:DD

DuPont de Nemours — DuPont — Technical Presentation (October 2015)

39 slides from DuPont de Nemours's technical presentation, Oct 6, 2015

  1. Slide 1: Major Milestones Achieved — MPTP Enters Next Phase

    Major Milestones Achieved — MPTP Enters Next Phase October 6, 2015

  2. Slide 2: DuPont Presenters

    DuPont Presenters Michael H. Scholla, Ph.D. Global Director, Regulatory and Standards; Medical Packaging Fellow Bruce A. Yost, Ph.D. Global Technical Director Karen Polkinghorne Packaging Engineer and MDM Specialist Margaret (Meg) Pyers Global Marketing Director 2 Copyright © 2015 DuPont. All rights

  3. Slide 3: Topics of Today's Discussion

    Topics of Today’s Discussion Guidance from U.S. FDA and Health Canada Tips for Submissions to Notified Bodies MPTP Interim Test Results after 7- and 10-Year Accelerated Aging Commercialization Plan We’re Still Here to Help 3 Copyright © 2015 DuPont. All rights reserved. The DuPont Oval Logo and Tyve

  4. Slide 4: Thank You

    Thank You Today would not have been possible without the collaboration and support of those listed here plus more than 55 MDMs Copyright © 2015 DuPont. All rights reserved. The DuPont Oval Logo and Tyvek® are trademarks or registered trademarks of E.I. du Pont de Nemours and Company or its affiliate

  5. Slide 5: Participating Regulatory Organizations

    Participating Regulatory Organizations U.S. FDA Center for Devices and Radiological Health (CDRH) Health Canada BSI Assurance UK Ltd LNE/G-MED SGS United Kingdom Limited TÜV Rheinland LGA Products GmbH TÜV SÜD Product Service GmbH China Food and Drug Administration (CFDA)-Jinan Quality Supervision a

  6. Slide 6: U.S. FDA CDRH Affirms Functional Equivalence

    U.S. FDA CDRH Affirms Functional Equivalence www.fda.gov www.areyouready.tyvek.com 6 Copyright © 2015 DuPont. All rights reserved. The DuPont Oval Logo and Tyvek® are trademarks or registered trademarks of E.I. du Pont de Nemours and Company or its affiliates. (10/15)

  7. Slide 7: U.S. FDA Letter — 2nd Paragraph

    U.S. FDA Letter — 2nd Paragraph 7 Copyright © 2015 DuPont. All rights reserved. The DuPont Oval Logo and Tyvek® are trademarks or registered trademarks of E.I. du Pont de Nemours and Company or its affiliates. (10/15)

  8. Slide 8: U.S. FDA Letter — Bullet Points

    U.S. FDA Letter — Bullet Points 8 Copyright © 2015 DuPont. All rights reserved. The DuPont Oval Logo and Tyvek® are trademarks or registered trademarks of E.I. du Pont de Nemours and Company or its affiliates. (10/15)

  9. Slide 9: What Is Legacy Tyvek?

    What Is Legacy Tyvek®? Now that we have received U.S. FDA affirmation of Functional Equivalence and are beginning commercialization, the term “Current Tyvek®” is no longer relevant Legacy Tyvek® is the new term for Tyvek® produced on the older manufacturing lines DuPont will use the terms Legacy Tyv

  10. Slide 10: Regulatory Update — Health Canada

    Regulatory Update — Health Canada “Health Canada Requirements for Manufacturers Relating to Manufacturing Change to Tyvek® 1073B and 1059B” was broadcast e-mail by Health Canada on May 7, 2014 and posted at www.areyouready.tyvek.com Individualized letters were sent by Health Canada on September 30,

  11. Slide 11: September 30, 2015 Licence Notification

    SEPTEMBER 30, 2015 LICENCE NOTIFICATION / AVIS DE LICENCE DU 30 SEPTEMBRE 2015 OPTION 1 ☐ None of the medical devices described in the “September 30, 2015 Licence Notification” use Tyvek materials / Aucun des instruments médicaux décrits dans l'Avis de licence du 30 septembre 2015 n'utilise le matér

  12. Slide 12: Health Canada — Attestation Codes (slide 1 of 2)

    Health Canada — Attestation Codes (slide 1 of 2) Code Defini*on NT • No Tyvek is used in any devices under this licence; or • Transi5on Tyvek will not be used for these devices (e.g. the devices on this licence do use Tyvek, but the licence is being cancelled by the manufacturer and therefore we will

  13. Slide 13: Health Canada — Attestation Codes (slide 2 of 2)

    Health Canada — Attestation Codes (slide 2 of 2) Code Defini*on AP The Tyvek package configura5on and steriliza5on method is NOT covered by DuPont’s tes5ng and there is a reasonable expecta5on that differences may nega5vely impact the device sterility over the stated shelf-­‐life. A medical device lice

  14. Slide 14: Attestations Page (slide 1 of 2)

    Attestations Page (slide 1 of 2) OPTION 1) ☐ None of the medical devices described in the attached “September 30, 2015 Licence Notification” use Tyvek materials / Aucun des instruments médicaux décrits dans l'Avis de licence du 30 septembre 2015 ci-joint n'utilise le matériel d'emballage Tyvek. I, a

  15. Slide 15: Attestations Page (slide 2 of 2)

    Attestations Page (slide 2 of 2) OPTION 2) ☐ As indicated in the attached “September 30, 2015 Licence Notification” table, there are licences that will use Transition Tyvek / Tel qu'il est indiqué dans le tableau de l'Avis de licence du 30 septembre 2015, certaines licences touchent des instruments

  16. Slide 16: Health Canada Acknowledgement

    Health Canada Acknowledgement Health Canada will send an acknowledgement e-mail to the regulatory contact once the attestation and licence listing have been validated for completeness and added to the manufacturer’s file. If an error is made in completing the table (i.e. multiple responses have been

  17. Slide 17: Health Canada Next Steps after Acknowledgement

    Health Canada Next Steps after Acknowledgement No further action, either because • The medical device does not use Tyvek; or • Transition Tyvek will not be used for these devices; or • The Tyvek configuration, sterilization method, and labelled shelf life are fully covered (clearly applicable and re

  18. Slide 18: Health Canada Summary

    Health Canada Summary Class III and IV Licence holders have/will receive an individualized communication from Health Canada • If your regulatory contact hasn’t received their package, contact Health Canada The two forms in this communication must be completed and returned by December 31, 2015 The as

  19. Slide 19: Review of Executive Summary with U.S. FDA, Health Canada and 5 Notified Bodies

    Review of Executive Summary with U.S. FDA, Health Canada and 5 Notified Bodies Met with each organization over a 3-week period to specifically address the 6 occurrences of non-equivalence or non-inferiority in greater detail than described in the Executive Summary Report* All were satisfied with our

  20. Slide 20: Tips for Submissions to Notified Bodies

    Tips for Submissions to Notified Bodies Have very specific discussions with your Notified Body regarding referencing reports or a requirement to include DuPont reports • Be mindful of confidentiality of Cell and Participant Reports Notified Bodies’ major concern was submissions by MDMs that simply c

  21. Slide 21: Regulatory Update — Japan

    Regulatory Update — Japan September 25, 2013 Guidance was to file a Minor Change Notification Form (Keibi Henkou Todoke); however, laws have changed Based upon new laws, NO ACTION IS REQUIRED; translation of new June 1, 2015 Guidance available on our website in the regulatory section If you file a M

  22. Slide 22: Regulatory Report Submission Status

    Regulatory Report Submission Status 22 Copyright © 2015 DuPont. All rights reserved. The DuPont Oval Logo and Tyvek® are trademarks or registered trademarks of E.I. du Pont de Nemours and Company or its affiliates. (10/15)

  23. Slide 23: Publication of MPTP Industry Summary Reports

    Publication of MPTP Industry Summary Reports Timing Pre-sterilization and Post-sterilization October 2014 Accelerated Aging (1 Year) February 2015 Accelerated Aging (3 Years) June 2015 Accelerated Aging (5 Years) July 2015 Real-Time Aging (1 Year) August 2015 Executive Summary August 2015 Accelerate

  24. Slide 24: MPTP Testing Update

    MPTP Testing Update Data to-date represents: more than 50,000 seal strength tests and 2,500+ microbial barrier tests In summary, the data indicates: • 796 out of 798 instances of seal strength Functional Equivalence • 468 out of 468 instances of microbial barrier Non-Inferiority • 14,039 out of 14,0

  25. Slide 25: MPTP Interim Test Results after 7-Year Accelerated Aging

    Industry Summary: MPTP Interim Test Results (7/11 Cells) after 7-Year Accelerated Aging, Pass/Fail Summary for Seal Strength — ASTM F88 25 Copyright © 2015 DuPont. All rights reserved. The DuPont Oval Logo and Tyvek® are trademarks or registered trademarks of E.I. du Pont de Nemours and Company or i

  26. Slide 26: MPTP Interim Test Results after 10-Year Accelerated Aging

    Industry Summary: MPTP Interim Test Results (3/11 Cells) after 10-Year Accelerated Aging, Pass/Fail Summary for Seal Strength — ASTM F88 26 Copyright © 2015 DuPont. All rights reserved. The DuPont Oval Logo and Tyvek® are trademarks or registered trademarks of E.I. du Pont de Nemours and Company or

  27. Slide 27: NEW Transition Protocol Material Data on Our Website

    NEW Transition Protocol Material Data on Our Website Effects of sterilization and 7-year accelerated aging on: • material puncture strength • material tensile strength • material elongation • material microbial barrier (ASTM F2638) Effects of sterilization and 10-year accelerated aging on: • cytotox

  28. Slide 28: All of this and more can be found on our website

    All of this and more can be found on our website at: www.areyouready.tyvek.com Documents on this website will be available through Testing Summary 5-Year Real-Time Aging (2019) Industry Executive Summary Report Specification Properties Effects of Sterilization and 7-Year Accelerated Aging 28 Copyrig

  29. Slide 29: Are You Ready Website – Regulatory Section

    Are You Ready Website – Regulatory Section U.S. FDA Letter Affirming Functional Equivalence Japan Guidance, June 2015 Health Canada Guidance, September 2015 29 Copyright © 2015 DuPont. All rights reserved. The DuPont Oval Logo and Tyvek® are trademarks or registered trademarks of E.I. du Pont de Nem

  30. Slide 30: Helpful Hints for MDMs

    Helpful Hints for MDMs U.S. FDA • Make sure you meet the 3 bullet points outlined in the U.S. FDA letter • Class II and III devices, place letter(s) in each applicable device record before beginning to use Transition Tyvek® European Notified Bodies • Complete risk assessments and notifications per g

  31. Slide 31: Updated DuPont Commercialization Plan

    Updated DuPont Commercialization Plan Both Legacy and Transition Tyvek® are now available from DuPont to SPMs We recognize the real-world dynamics of our customers’ needs, regulatory submissions and short-term supply constraints DuPont is extending the availability of Legacy Tyvek® through June 2016

  32. Slide 32: 2015 Will Be a Record Production Year for Tyvek

    2015 Will Be a Record Production Year for Tyvek® Sold into Medical and Pharmaceutical Packaging While we expect to ship more medical packaging product this year than any other year in recent history, the demand for these products is more than 40% higher than the same time last year As a result, we a

  33. Slide 33: Upcoming Events and Other Ways to Stay Informed

    Upcoming Events and Other Ways to Stay Informed Attend a DuPont Seminar near you: • Dallas, TX – October 20 • East Lansing, MI – November 10 Visit us at Medica/Compamed 2015 in Düsseldorf, Germany – November 16-19 Global webcasts – available on-demand for up to a year at www.medicalpackagingcommunit

  34. Slide 34: Bottom Line

    Bottom Line The U.S. FDA Affirmed Functional Equivalence Health Canada Issued Guidance Notified Bodies Are Approving Submissions Transition Tyvek® is now interchangeable with Legacy Tyvek® Use of Transition Tyvek® should be documented in each applicable device record We have extended the availabilit

  35. Slide 35: Thank You to the hundreds of DuPont employees

    Recognizing the DuPont MPTP Team and Our Media Partners Thank You to the hundreds of DuPont employees around the world from R&D, technical, manufacturing, QA, regulatory, sales and marketing who have dedicated their time and talent to help ensure the success of MPTP. 35 Copyright © 2015 DuPont. All

  36. Slide 36: In Closing, Why Tyvek?

    In Closing, Why Tyvek®? For more than 40 years, you have relied on DuPont products, technical expertise and global response capabilities We’re committed to the medical and pharmaceutical industries and the protection of people and critical processes around the world • Continuing to invest in our man

  37. Slide 37: Questions?

    Questions? www.transition.tyvek.com www.areyouready.tyvek.com 37 Copyright © 2015 DuPont. All rights reserved. The DuPont Oval Logo and Tyvek® are trademarks or registered trademarks of E.I. du Pont de Nemours and Company or its affiliates. (10/15)

  38. Slide 38: Thank you!

    Thank you! Today’s webcast will be archived for one year for on-demand viewing within this environment For any additional questions, please contact us: Daphne Allen, Editor, Pharmaceutical & Medical Packaging News at daphne.allen@ubm.com Or a member of the DuPont team at www.transition.tyvek.com 38

  39. Slide 39: Copyright © 2015 DuPont. All rights reserved. The DuPont Oval Logo, DuPont ™ and

    Copyright © 2015 DuPont. All rights reserved. The DuPont Oval Logo, DuPont™ and Tyvek® are trademarks or registered trademarks of E.I. du Pont de Nemours and Company or its affiliates. 39

DuPont — Technical Presentation (October 2015) on 6ix